Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ, Lau R, Ingram LC, Wiernikowski JT, Grant R, Howard DR, Perrotta M, Barr R, Dempsey E, Greenberg ML, Leclerc JM. Coppes MJ, et al. Among authors: dempsey e. Med Pediatr Oncol. 1999 Aug;33(2):99-105. doi: 10.1002/(sici)1096-911x(199908)33:2<99::aid-mpo7>3.0.co;2-p. Med Pediatr Oncol. 1999. PMID: 10398184 Clinical Trial.
Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ, Yanofsky R, Pritchard S, Leclerc JM, Howard DR, Perrotta M, Keays S, Pyesmany A, Dempsey E, Pratt CB. Coppes MJ, et al. Among authors: dempsey e. J Pediatr Hematol Oncol. 1999 Jul-Aug;21(4):274-83. doi: 10.1097/00043426-199907000-00007. J Pediatr Hematol Oncol. 1999. PMID: 10445889
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Lofters WS, et al. Among authors: dempsey e. J Clin Oncol. 1997 Aug;15(8):2966-73. doi: 10.1200/JCO.1997.15.8.2966. J Clin Oncol. 1997. PMID: 9256141 Clinical Trial.
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Pater JL, et al. Among authors: dempsey e. Ann Oncol. 1997 Feb;8(2):181-5. doi: 10.1023/a:1008247830641. Ann Oncol. 1997. PMID: 9093728 Free article. Clinical Trial.
Usefulness of sustained-release diltiazem for stable angina pectoris.
Klinke WP, Juneau M, Grace M, Kostuk WJ, Pflugfelder P, Maranda CR, Warnica W, Chin C, Annable L, Dempsey EE, et al. Klinke WP, et al. Among authors: dempsey ee. Am J Cardiol. 1989 Dec 1;64(19):1249-52. doi: 10.1016/0002-9149(89)90562-6. Am J Cardiol. 1989. PMID: 2511743 Clinical Trial.
597 results